GlassScriptPhysician profile
Katherine Diaz
NPI 1255767455
$2,149.76
in general payments reported to CMS, 2019-2025
20 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $618 · 2023: $384 · 2024: $246 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.79 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $684.10 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Bayer Healthcare Pharmaceuticals INC. | $194.98 | 2022 | |
| Daiichi Sankyo INC. | $172.81 | 2024-2025 | Injectafer, Datroway, Enhertu |
| Astrazeneca Pharmaceuticals LP | $153.72 | 2023-2025 | Calquence, Enhertu |
| Beone Medicines USA, INC. | $130.50 | 2025 | Brukinsa |
| Kite Pharma, INC. | $124.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.02 | 2022 | |
| Abbvie INC. | $93.13 | 2021-2025 | |
| Genzyme Corporation | $72.61 | 2021-2025 | |
| Beigene USA, INC. | $57.92 | 2024-2025 | Brukinsa |
| Johnson & Johnson Surgical Vision, INC. | $55.65 | 2021-2025 | Tecnis Iol |
| Jazz Pharmaceuticals INC. | $50.56 | 2021 | |
| Adc Therapeutics America, INC. | $45.94 | 2024 | |
| Pfizer INC. | $38.67 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $35.26 | 2022-2023 | Clonoseq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $33.54 | 2025 | |
| Novartis Pharmaceuticals Corporation | $32.06 | 2022 | |
| Lilly USA, LLC | $17.95 | 2024 | Jaypirca |
| Incyte Corporation | $17.26 | 2025 | Niktimvo |
| Coherus Oncology, INC. | $15.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.